Tekla Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Tekla Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-294,749	Closed	-$2.84M	–	166
2017 Q3	$2.84M	Buy	294,749 +201,400	+216%	+$2.09M	0.1%	104
2017 Q2	$1.1M	Hold	93,349	–	–	0.04%	128
2017 Q1	$1.2M	Hold	93,349	–	–	0.05%	125
2016 Q4	$1.14M	Hold	93,349	–	–	0.05%	125
2016 Q3	$1.1M	Hold	93,349	–	–	0.04%	134
2016 Q2	$812K	Hold	93,349	–	–	0.03%	149
2016 Q1	$492K	Hold	93,349	–	–	0.02%	135
2015 Q4	$724K	Sell	93,349 -121,800	-57%	-$936K	0.03%	128
2015 Q3	$1.69M	Hold	215,149	–	–	0.06%	146
2015 Q2	$1.95M	Buy	+215,149	New	+$2.17M	0.07%	99

Other funds holding GNMK

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tekla Capital Management's GNMK Position: Q4 2017 in Review

Tekla Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2017, closing a stake of 294,749 shares — an estimated $2.84M sold.

Tekla Capital Management first reported a position in GNMK in Q2 2015 and held it in 10 quarters. The position peaked at $2.84M in Q3 2017. 99 funds tracked by Wall St. Rank hold GNMK as of Q4 2017.

Tekla Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q4 2017 after selling out during the quarter.
Tekla Capital Management sold 294,749 GenMark Diagnostics, Inc shares in Q4 2017, an estimated $2.84M.
Tekla Capital Management first reported a position in GenMark Diagnostics, Inc in Q2 2015 and held it in 10 quarters.
Tekla Capital Management's GenMark Diagnostics, Inc position peaked at $2.84M in Q3 2017.
99 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2017.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.